AVITA Medical (RCEL) 2024 Cantor Fitzgerald Global Healthcare Conference summary

Strategic transformation and leadership

• Undergoing a strategic transformation to become a global wound care company, expanding product portfolio and automating client systems.

• Leadership changes included CEO Jim Corbett taking over commercial operations and hiring Robin Vandenburgh to strengthen the commercial team.

Product innovation and automation

• RECELL GO, an automated system, received FDA approval in mid-2024, replacing the manual process and reducing OR time and staff requirements.

• The system consists of a durable device (RPD) loaned to hospitals and a disposable cartridge (RPK), with the durable used up to 200 times before replacement.

• RECELL GO Mini, designed for smaller wounds, is expected to receive FDA approval by December 2024 and launch in January 2025.

Market expansion and regulatory milestones

• FDA approval for full-thickness skin defects expanded the addressable market from 35,000 burns to 400,000 wounds annually.

• Conversion of all accounts to RECELL GO is targeted for Q3 2024, with 90-95% expected by quarter-end.

• International expansion focuses on Europe, Australia, Japan, and the UK, using third-party distributors to minimize costs.

• CE mark for RECELL GO in Europe is expected within 30 days, enabling imminent product launch.